Trim32-based new differentiation therapy for neuroblastoma
Project/Area Number |
15K09674
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Pediatrics
|
Research Institution | 地方独立行政法人佐賀県医療センター好生館(ライフサイエンス研究所) |
Principal Investigator |
IZUMI Hideki 地方独立行政法人佐賀県医療センター好生館(ライフサイエンス研究所), ライフサイエンス研究所, 部長 (10397987)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 分化誘導療法 / 神経芽腫 / 非対称分裂 |
Outline of Final Research Achievements |
The purpose of this study is to clarify the molecular target of Trim32-based differentiation therapy for neuroblastoma cells and to establish a new treatment method of neuroblastoma by a novel mechanism. We attempted to identify new target gene (s) in Trim32-mediated cell differentiation by cDNA microarray. As a result of analysis by cDNA microarray, CDKN1A was identified as a gene whose expression increased in Trim32-mediated cell differentiation. When CDKN1A is knocked down in human neuroblastoma cells, 13-cis-retinoid (13-cis) mediated cell differentiation ability decreased. Furthermore, when 13-cis treatment is performed on human neuroblastoma cells after transfection of CDKN1A cDNA expression vector, the differentiation inducing ability significantly increased.
|
Report
(4 results)
Research Products
(7 results)